Compare Analog Devices, Inc. (ADI) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Quest Diagnostics Inc — how do they compare? Analog Devices, Inc. trades at $384.2 (market cap $187.67B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Analog Devices, Inc. is far larger — about 7.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| ADI | DGX | |
|---|---|---|
Market Cap | $187.67B | $26.21B |
Sector | Technology | Health |
52-Week High | $445.48 | $238.50 |
52-Week Low | $225.20 | $173.49 |
Enterprise Value | $192.92B | $31.97B |
Dividend Yield | 1.14% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.98, up 0.27% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $472.29 highlight positive momentum. The company maintains robust profitability with a 26.01% net income margin and a dividend payout of $1.10, supported by solid cash flow from operations of $4.81 billion in 2025.
Outlook remains favorable with projected revenue growth to $12.7 billion in 2026, though elevated valuation ratios and competitive pressures in semiconductors pose risks. Institutional buying and a lack of sell ratings underscore confidence, but investors should monitor debt levels and market volatility.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
